• AAPL 166.82
  • TSLA 144.61
  • AMZN 179.515
  • MSFT 407.055
  • INTC 34.27
  • EURUSD 1.0712
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. HOOK.NASDAQ

Hookipa Pharma Inc (HOOK NASDAQ) stock market data APIs

$0.73 -0.04(-5.2%) as of April 23, 2024

Hookipa Pharma Inc Financial Data Overview

0.765
0.73
-
0.8
0.7233
0.41-2.05
69 958 K
96 551 K
20 129 K
-0.22
1.018
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'HOOK',
Type: 'Common Stock',
Name: 'Hookipa Pharma Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: NULL,
CIK: '1760542',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2019-04-18',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Hookipa Pharma Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 20 129 K
  • EBITDA -81 376 000
  • Earnings Per Share -0.86
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Hookipa Pharma Inc Earnings via APIs

  • Latest Release 2024-03-22
  • EPS/Forecast -0.19

Get Hookipa Pharma Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Hookipa Pharma Inc latest news via APIs

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead’), to be evaluated as a potential curative regimen for human immunodeficiency virus (HIV) Phas...
  • CLINICAL STUDY
  • COLLABORATION
  • COMPANY ANNOUNCEMENT
  • HB-500
  • HIV
  • HOOKIPA
  • HOOKIPA PHARMA INC
  • NASDAQ:HOOK
  • PRODUCT / SERVICES ANNOUNCEMENT

HOOKIPA Pharma Inc. Reports Increased Revenue and Higher R&D Expenses in Q3 2023

Revenue for Q3 2023 increased to $6.9 million, up from $2.2 million in Q3 2022. Research and Development expenses rose to $24.6 million, reflecting a $6.3 million increase year-over-year. Cash, cash e...
Do you have any questions?
support@eodhistoricaldata.com